구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose)) Daiichi Sankyo Co., Ltd.·Non-Small Cell Lung Cancer Metasta… 149 trials·t½ 53 h |
|---|---|
Overview Program | Patritumab Deruxtecan (Fixed dose) |
Overview Company | Daiichi Sankyo Co., Ltd. |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer Metastatic |
Overview Indication | Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | inhibits human epidermal growth factor receptor 2 (HER2) while sparing wild-type epidermal growth factor receptor |
MoA Biomarker | Biomarker of Methylthioadenosine Phosphorylase-Selective Protein Arginine Methyltransferase 5 Inhibition |
PK/PD Half-life | 53 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Analysis of Seriousness and Preventability of Adverse Drug Reactions in Patients at a Tertiary Care Teaching Hospital: A Case Series.. This case series describes three serious adverse drug reactions (ADRs) reported from tertiary care teaching hospitals and analyses their seriousness and preventability. The cases included fixed drug eruption associated with paracetamol/amoxicillin exposure, Stevens… |
Toxicology CRS | Reported |
Clinical Safety signal | Analysis of Seriousness and Preventability of Adverse Drug Reactions in Patients at a Tertiary Care Teaching Hospital: A Case Series.. This case series describes three serious adverse drug reactions (ADRs) reported from tertiary care teaching hospitals and analyses their seriousness and preventability. The cases included fixed drug eruption associated with paracetamol/amoxicillin exposure, Stevens… |
Clinical Selected reported efficacy | ORR 64% |
Clinical Reported ORR | 56% |
Clinical Reported PFS | 5.5 |
Clinical Result source | ClinicalTrials.gov NCT04619004 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04619004 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose)) Daiichi Sankyo Co., Ltd.·Non-Small Cell Lung Cancer Metasta… 149 trials·t½ 53 h |
|---|---|
Overview Program | Patritumab Deruxtecan (Fixed dose) |
Overview Company | Daiichi Sankyo Co., Ltd. |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer Metastatic |
Overview Indication | Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | inhibits human epidermal growth factor receptor 2 (HER2) while sparing wild-type epidermal growth factor receptor |
MoA Biomarker | Biomarker of Methylthioadenosine Phosphorylase-Selective Protein Arginine Methyltransferase 5 Inhibition |
PK/PD Half-life | 53 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Analysis of Seriousness and Preventability of Adverse Drug Reactions in Patients at a Tertiary Care Teaching Hospital: A Case Series.. This case series describes three serious adverse drug reactions (ADRs) reported from tertiary care teaching hospitals and analyses their seriousness and preventability. The cases included fixed drug eruption associated with paracetamol/amoxicillin exposure, Stevens… |
Toxicology CRS | Reported |
Clinical Safety signal | Analysis of Seriousness and Preventability of Adverse Drug Reactions in Patients at a Tertiary Care Teaching Hospital: A Case Series.. This case series describes three serious adverse drug reactions (ADRs) reported from tertiary care teaching hospitals and analyses their seriousness and preventability. The cases included fixed drug eruption associated with paracetamol/amoxicillin exposure, Stevens… |
Clinical Selected reported efficacy | ORR 64% |
Clinical Reported ORR | 56% |
Clinical Reported PFS | 5.5 |
Clinical Result source | ClinicalTrials.gov NCT04619004 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04619004 |
추천 비교
추천 비교